Biofrontera AG reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was EUR 6.83 million compared to EUR 5.38 million a year ago. Net loss was EUR 5.1 million compared to EUR 5.8 million a year ago. Basic loss per share from continuing operations was EUR 0.09 compared to EUR 0.1 a year ago.
For the nine months, sales was EUR 21.91 million compared to EUR 18.47 million a year ago. Net loss was EUR 41.85 million compared to EUR 14.67 million a year ago. Basic loss per share from continuing operations was EUR 0.74 compared to EUR 0.26 a year ago.